In the landscape of modern drug discovery, the traditional animal study has long been regarded as a linear, resource-intensive necessity. A cohort of animals is dosed, tissues are harvested, slides are generated, and a pathologist renders a final report. Once the data is archived, the glass slides—and the biological insights locked within them—often gather dust.
However, a paradigm shift is underway. Propelled by the rapid adoption of digital pathology, researchers are transforming these "one-way" archives into goldmines of reusable data. By digitizing tissues and applying advanced computational analysis, the industry is moving toward a future where we extract more knowledge from the animals already involved in studies, effectively reducing the need for new animal experiments.
Main Facts: The Digital Transformation of Histology
The catalyst for this change was the COVID-19 pandemic. As lockdowns prevented pathologists from accessing physical microscopes, the forced migration to digital slide viewing became a necessity. What began as a remote-work workaround has evolved into a robust scientific infrastructure.
Today, digital pathology—the practice of converting glass slides into high-resolution pixel-based images—has unlocked the ability to train machine learning models on biological patterns. According to Aleksandra Zuraw, DVM, PhD, a veterinary pathologist at Charles River Laboratories, the industry is moving away from the static, subjective "pathology report" toward a data-centric model.
"Before, the pathology endpoint was just a report," Dr. Zuraw explains. "Now you have the digitized slide, which is pixels." This shift allows for the application of artificial intelligence (AI) to recognize molecular changes, gene expression patterns, and subtle morphological shifts that the human eye might overlook. By pairing these images with original toxicology data, researchers can revisit past studies to answer new scientific questions without the ethical and financial cost of initiating a new, live-animal trial.
A Chronology of the Shift toward Non-Animal Methods (NAMs)
The transition toward alternative methods is not merely a technological trend; it is a regulatory imperative gaining momentum over the last several years.
- 2019–2020: Early demonstrations of virtual staining and digital histology gain traction, proving that software can simulate the appearance of stained tissue without traditional chemical reagents. The pandemic serves as a global accelerant, forcing pathology departments to adopt digital workflows for remote operations.
- 2022: The United States Congress enacts the FDA Modernization Act 2.0, a landmark piece of legislation that officially permits the use of non-animal methods to support applications for human clinical trials. This signaled a fundamental change in how the FDA evaluates drug safety.
- April 2024: Charles River Laboratories launches its Alternative Methods Advancement Project, signaling a corporate-level commitment to reducing reliance on traditional animal models through "data mining" and virtual control groups.
- April 2025: The FDA releases a comprehensive roadmap for reducing animal testing in preclinical safety studies. The document outlines a multi-year strategy to transition from animal-centric testing to New Approach Methodologies (NAMs), initially focusing on monoclonal antibodies before expanding to complex biologics.
- September 2026: The FDA issues updated regulations further codifying the role of innovative alternatives to animal testing, solidifying the regulatory framework for digital and molecular research.
Supporting Data: The Power of Virtual Controls and FFPE Blocks
One of the most immediate impacts of this transition is the creation of "virtual control groups." In standard toxicology, a significant percentage of animals are designated as controls—receiving no drug to serve as a baseline for comparison. By leveraging robust historical databases of matched, high-quality data, researchers can replace these live control animals with virtual equivalents.
"Control animals are always a big fraction of every study," says Dr. Zuraw. Through simple arithmetic, replacing these with verified historical controls drastically reduces the total animal count. However, this requires rigorous validation. The Charles River team is currently focused on generating enough matched data to provide virtual controls with the same, if not higher, confidence levels than concurrent controls.
Furthermore, the industry is finding new value in Formalin-Fixed, Paraffin-Embedded (FFPE) blocks. For decades, these blocks have been stored in long-term archives. While traditional histology looked only at the physical structure of the tissue, modern molecular techniques allow for the analysis of gene expression and protein levels within these archived samples.
The Organisation for Economic Co-operation and Development (OECD) released guidance in 2025 specifically addressing the use of these samples for "omics" analysis. The guidance emphasizes that while sample preparation and storage quality are critical, preserved tissues represent a massive, untapped longitudinal dataset that remains tied to the original study’s context, dosing information, and clinical outcomes.
Official Responses and Regulatory Climate
The regulatory environment has undergone a sea change. Historically, the FDA and global health authorities were risk-averse, favoring the "tried and true" methodology of animal testing. However, the current regulatory push is proactive.
The FDA’s 2025 roadmap is particularly significant because it establishes a timeline for replacing animal studies with NAMs. The agency’s long-term goal—to make animal studies the exception rather than the rule within the next three to five years—has forced pharmaceutical companies and contract research organizations (CROs) to rapidly innovate.
This is not just about checking boxes for regulators; it is about scientific efficiency. As Dr. Zuraw notes, when a researcher realizes a new question about a drug’s mechanism of action after a study has concluded, the traditional response was to conduct a new experiment. Today, if the tissue exists in an archive, the digital or molecular answer can be found in the same block, essentially "recycling" the animal’s contribution to science.
Implications: The "Snowball Effect" of Digital Innovation
The implications for the future of drug discovery are profound, both ethically and operationally.
1. The Death of the "One-Way Street"
The shift from glass slides to digital pixels turns pathology into a truly iterative science. Researchers can now build longitudinal databases where a single slide is analyzed multiple times by different algorithms as technology evolves. This prevents the "data loss" that occurred when physical slides were relegated to storage bins.
2. The Rise of Virtual Staining
Perhaps the most "cutting-edge" development mentioned by experts is virtual staining. By scanning unstained tissue and using software to generate the color-coded appearance of a standard H&E (hematoxylin and eosin) stain, laboratories can potentially bypass the costly, time-consuming, and toxic chemical staining process. This is not merely a cost-saving measure; it is a way to standardize results across different global labs, removing the variability inherent in manual slide preparation.
3. The Need for Early Adopters
While the technology is promising, the transition remains in its early stages. Dr. Zuraw stresses that the industry needs "early adopters" to generate the necessary precedent. When a pioneer lab successfully uses an AI-based virtual control group to satisfy a regulatory requirement, it creates a blueprint for others to follow. This "troubleshooting" phase is crucial; once the precedent is set, the transition will likely shift from a slow adoption to a "snowball effect," where the integration of digital, molecular, and archival data becomes the industry standard.
4. Ethical and Financial Efficiency
Ultimately, the primary driver is the move toward the "3Rs": Replacement, Reduction, and Refinement. By extracting more from existing tissue, labs can reduce the number of animals required for development. This leads to shorter, cheaper, and more ethical drug discovery cycles, which could ultimately lower the cost of bringing life-saving therapies to market.
Conclusion: A New Era of Data-Driven Pathology
The evolution of digital pathology is proof that the most significant innovations in drug discovery are sometimes not new drugs, but new ways of looking at the data we already possess. By shifting from the analog, terminal processes of the past to the digitized, analytical processes of the present, the scientific community is finding a way to honor the legacy of preclinical research while fundamentally reshaping its future.
As laboratories continue to bridge the gap between regulatory requirements and emerging AI-driven methodologies, the "one-way street" of pathology will continue to disappear. In its place, a multi-lane, digital highway is emerging—one that is faster, more ethical, and significantly more informed by the wealth of data hidden in the archives of the past.
About the Author
